Gattai, Minoli, Agostinelli assisted Enthera S.r.l., for the contractual and corporate aspects, in the Euro 28 milion Series A Investment in Enthera S.r.l., a biotech company that develops first-in-class biologics for several underserved autoimmune conditions in order to restore the regenerative capacity of stem cells.
The transaction represents in Italy the largest Series A fundraising in the biotech field, supported by a venture capital company. It is also the first investment in an Italian biotech company by AbbVie Ventures, the venture capital group of AbbVie, American multinational company active in biopharmaceutical and listed on the NYSE. The investment was led by Sofinnova Partners, with the contribution on the Juvenile Diabetes Research Foundation and other Italian investors, including a group coordinated by Banor Sim and one by Banca Profilo through Arepo fiduciaria and Indaco.
Gattai, Minoli, Agostinelli, Partners assisted Enthera S.r.l. with a team led by partner Nicola Brunetti and associates Enrico Candotti and Nicola Occhipinti and by Partner Silvia D’Alberti for the Golden Power aspects.